Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Closing and Opening Holes in the Glycan Shield of HIV-1 Envelope Glycoprotein SOSIP Trimers Can Redirect the Neutralizing Antibody Response to the Newly Unmasked Epitopes.

Ringe RP, Pugach P, Cottrell CA, LaBranche CC, Seabright GE, Ketas TJ, Ozorowski G, Kumar S, Schorcht A, van Gils MJ, Crispin M, Montefiori DC, Wilson IA, Ward AB, Sanders RW, Klasse PJ, Moore JP.

J Virol. 2019 Feb 5;93(4). pii: e01656-18. doi: 10.1128/JVI.01656-18. Print 2019 Feb 15.

PMID:
30487280
2.

Collusion between neutralizing antibodies and other immune factions in the destruction of adenoviral vectors.

Klasse PJ.

Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):10201-10203. doi: 10.1073/pnas.1814275115. Epub 2018 Sep 19. No abstract available.

PMID:
30232262
3.

Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro.

Ozorowski G, Cupo A, Golabek M, LoPiccolo M, Ketas TA, Cavallary M, Cottrell CA, Klasse PJ, Ward AB, Moore JP.

J Virol. 2018 Jun 13;92(13). pii: e00381-18. doi: 10.1128/JVI.00381-18. Print 2018 Jul 1.

4.

Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.

Klasse PJ, Ketas TJ, Cottrell CA, Ozorowski G, Debnath G, Camara D, Francomano E, Pugach P, Ringe RP, LaBranche CC, van Gils MJ, Bricault CA, Barouch DH, Crotty S, Silvestri G, Kasturi S, Pulendran B, Wilson IA, Montefiori DC, Sanders RW, Ward AB, Moore JP.

PLoS Pathog. 2018 Feb 23;14(2):e1006913. doi: 10.1371/journal.ppat.1006913. eCollection 2018 Feb.

5.

Immunogenicity in Rabbits of HIV-1 SOSIP Trimers from Clades A, B, and C, Given Individually, Sequentially, or in Combination.

Torrents de la Peña A, de Taeye SW, Sliepen K, LaBranche CC, Burger JA, Schermer EE, Montefiori DC, Moore JP, Klasse PJ, Sanders RW.

J Virol. 2018 Mar 28;92(8). pii: e01957-17. doi: 10.1128/JVI.01957-17. Print 2018 Apr 15.

6.

cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV-1 envelope glycoprotein vaccine candidate.

Dey AK, Cupo A, Ozorowski G, Sharma VK, Behrens AJ, Go EP, Ketas TJ, Yasmeen A, Klasse PJ, Sayeed E, Desaire H, Crispin M, Wilson IA, Sanders RW, Hassell T, Ward AB, Moore JP.

Biotechnol Bioeng. 2018 Apr;115(4):885-899. doi: 10.1002/bit.26498. Epub 2017 Dec 11.

7.

High-Throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers.

Sullivan JT, Sulli C, Nilo A, Yasmeen A, Ozorowski G, Sanders RW, Ward AB, Klasse PJ, Moore JP, Doranz BJ.

J Virol. 2017 Oct 27;91(22). pii: e00862-17. doi: 10.1128/JVI.00862-17. Print 2017 Nov 15.

8.

Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo.

Medina-Ramírez M, Garces F, Escolano A, Skog P, de Taeye SW, Del Moral-Sanchez I, McGuire AT, Yasmeen A, Behrens AJ, Ozorowski G, van den Kerkhof TLGM, Freund NT, Dosenovic P, Hua Y, Gitlin AD, Cupo A, van der Woude P, Golabek M, Sliepen K, Blane T, Kootstra N, van Breemen MJ, Pritchard LK, Stanfield RL, Crispin M, Ward AB, Stamatatos L, Klasse PJ, Moore JP, Nemazee D, Nussenzweig MC, Wilson IA, Sanders RW.

J Exp Med. 2017 Sep 4;214(9):2573-2590. doi: 10.1084/jem.20161160. Epub 2017 Aug 28.

9.

Improving the Immunogenicity of Native-like HIV-1 Envelope Trimers by Hyperstabilization.

Torrents de la Peña A, Julien JP, de Taeye SW, Garces F, Guttman M, Ozorowski G, Pritchard LK, Behrens AJ, Go EP, Burger JA, Schermer EE, Sliepen K, Ketas TJ, Pugach P, Yasmeen A, Cottrell CA, Torres JL, Vavourakis CD, van Gils MJ, LaBranche C, Montefiori DC, Desaire H, Crispin M, Klasse PJ, Lee KK, Moore JP, Ward AB, Wilson IA, Sanders RW.

Cell Rep. 2017 Aug 22;20(8):1805-1817. doi: 10.1016/j.celrep.2017.07.077.

10.

HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers.

Capucci S, Wee EG, Schiffner T, LaBranche CC, Borthwick N, Cupo A, Dodd J, Dean H, Sattentau Q, Montefiori D, Klasse PJ, Sanders RW, Moore JP, Hanke T.

PLoS One. 2017 Aug 9;12(8):e0181886. doi: 10.1371/journal.pone.0181886. eCollection 2017.

11.

Reducing V3 Antigenicity and Immunogenicity on Soluble, Native-Like HIV-1 Env SOSIP Trimers.

Ringe RP, Ozorowski G, Rantalainen K, Struwe WB, Matthews K, Torres JL, Yasmeen A, Cottrell CA, Ketas TJ, LaBranche CC, Montefiori DC, Cupo A, Crispin M, Wilson IA, Ward AB, Sanders RW, Klasse PJ, Moore JP.

J Virol. 2017 Jul 12;91(15). pii: e00677-17. doi: 10.1128/JVI.00677-17. Print 2017 Aug 1.

12.

A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure.

Lee JH, Andrabi R, Su CY, Yasmeen A, Julien JP, Kong L, Wu NC, McBride R, Sok D, Pauthner M, Cottrell CA, Nieusma T, Blattner C, Paulson JC, Klasse PJ, Wilson IA, Burton DR, Ward AB.

Immunity. 2017 Apr 18;46(4):690-702. doi: 10.1016/j.immuni.2017.03.017.

13.

Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes.

Ringe RP, Ozorowski G, Yasmeen A, Cupo A, Cruz Portillo VM, Pugach P, Golabek M, Rantalainen K, Holden LG, Cottrell CA, Wilson IA, Sanders RW, Ward AB, Klasse PJ, Moore JP.

J Virol. 2017 May 26;91(12). pii: e00264-17. doi: 10.1128/JVI.00264-17. Print 2017 Jun 15.

14.

Quantitative correlation between infectivity and Gp120 density on HIV-1 virions revealed by optical trapping virometry.

DeSantis MC, Kim JH, Song H, Klasse PJ, Cheng W.

J Biol Chem. 2017 Feb 17;292(7):3061. doi: 10.1074/jbc.A116.729210. No abstract available.

15.

Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664.

Acharya K, Rashad AA, Moraca F, Klasse PJ, Moore JP, Abrams C, Chaiken I.

Proteins. 2017 May;85(5):843-851. doi: 10.1002/prot.25238. Epub 2017 Mar 11.

16.

An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability.

van Gils MJ, van den Kerkhof TL, Ozorowski G, Cottrell CA, Sok D, Pauthner M, Pallesen J, de Val N, Yasmeen A, de Taeye SW, Schorcht A, Gumbs S, Johanna I, Saye-Francisco K, Liang CH, Landais E, Nie X, Pritchard LK, Crispin M, Kelsoe G, Wilson IA, Schuitemaker H, Klasse PJ, Moore JP, Burton DR, Ward AB, Sanders RW.

Nat Microbiol. 2016 Nov 14;2:16199. doi: 10.1038/nmicrobiol.2016.199.

17.

HIV-1 Escape from a Peptidic Anchor Inhibitor through Stabilization of the Envelope Glycoprotein Spike.

Eggink D, de Taeye SW, Bontjer I, Klasse PJ, Langedijk JPM, Berkhout B, Sanders RW.

J Virol. 2016 Nov 14;90(23):10587-10599. doi: 10.1128/JVI.01616-16. Print 2016 Dec 1.

18.

Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C.

Klasse PJ, LaBranche CC, Ketas TJ, Ozorowski G, Cupo A, Pugach P, Ringe RP, Golabek M, van Gils MJ, Guttman M, Lee KK, Wilson IA, Butera ST, Ward AB, Montefiori DC, Sanders RW, Moore JP.

PLoS Pathog. 2016 Sep 14;12(9):e1005864. doi: 10.1371/journal.ppat.1005864. eCollection 2016 Sep.

19.

Quantitative Correlation between Infectivity and Gp120 Density on HIV-1 Virions Revealed by Optical Trapping Virometry.

DeSantis MC, Kim JH, Song H, Klasse PJ, Cheng W.

J Biol Chem. 2016 Jun 17;291(25):13088-97. doi: 10.1074/jbc.M116.729210. Epub 2016 Apr 25. Erratum in: J Biol Chem. 2017 Feb 17;292(7):3061.

20.

Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein.

Behrens AJ, Vasiljevic S, Pritchard LK, Harvey DJ, Andev RS, Krumm SA, Struwe WB, Cupo A, Kumar A, Zitzmann N, Seabright GE, Kramer HB, Spencer DI, Royle L, Lee JH, Klasse PJ, Burton DR, Wilson IA, Ward AB, Sanders RW, Moore JP, Doores KJ, Crispin M.

Cell Rep. 2016 Mar 22;14(11):2695-706. doi: 10.1016/j.celrep.2016.02.058. Epub 2016 Mar 10.

21.

Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes.

de Taeye SW, Ozorowski G, Torrents de la Peña A, Guttman M, Julien JP, van den Kerkhof TL, Burger JA, Pritchard LK, Pugach P, Yasmeen A, Crampton J, Hu J, Bontjer I, Torres JL, Arendt H, DeStefano J, Koff WC, Schuitemaker H, Eggink D, Berkhout B, Dean H, LaBranche C, Crotty S, Crispin M, Montefiori DC, Klasse PJ, Lee KK, Moore JP, Wilson IA, Ward AB, Sanders RW.

Cell. 2015 Dec 17;163(7):1702-15. doi: 10.1016/j.cell.2015.11.056.

22.

How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses.

Klasse PJ.

Expert Rev Vaccines. 2016;15(3):295-311. doi: 10.1586/14760584.2016.1128831. Epub 2016 Jan 6. Review.

23.

Binding of inferred germline precursors of broadly neutralizing HIV-1 antibodies to native-like envelope trimers.

Sliepen K, Medina-Ramírez M, Yasmeen A, Moore JP, Klasse PJ, Sanders RW.

Virology. 2015 Dec;486:116-20. doi: 10.1016/j.virol.2015.08.002. Epub 2015 Oct 1.

24.

Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike.

Lee JH, Leaman DP, Kim AS, Torrents de la Peña A, Sliepen K, Yasmeen A, Derking R, Ramos A, de Taeye SW, Ozorowski G, Klein F, Burton DR, Nussenzweig MC, Poignard P, Moore JP, Klasse PJ, Sanders RW, Zwick MB, Wilson IA, Ward AB.

Nat Commun. 2015 Sep 25;6:8167. doi: 10.1038/ncomms9167.

25.

Design and structure of two HIV-1 clade C SOSIP.664 trimers that increase the arsenal of native-like Env immunogens.

Julien JP, Lee JH, Ozorowski G, Hua Y, Torrents de la Peña A, de Taeye SW, Nieusma T, Cupo A, Yasmeen A, Golabek M, Pugach P, Klasse PJ, Moore JP, Sanders RW, Ward AB, Wilson IA.

Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):11947-52. doi: 10.1073/pnas.1507793112. Epub 2015 Sep 8.

26.

Influences on the Design and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers.

Ringe RP, Yasmeen A, Ozorowski G, Go EP, Pritchard LK, Guttman M, Ketas TA, Cottrell CA, Wilson IA, Sanders RW, Cupo A, Crispin M, Lee KK, Desaire H, Ward AB, Klasse PJ, Moore JP.

J Virol. 2015 Dec;89(23):12189-210. doi: 10.1128/JVI.01768-15. Epub 2015 Aug 26.

27.

Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.

Hu JK, Crampton JC, Cupo A, Ketas T, van Gils MJ, Sliepen K, de Taeye SW, Sok D, Ozorowski G, Deresa I, Stanfield R, Ward AB, Burton DR, Klasse PJ, Sanders RW, Moore JP, Crotty S.

J Virol. 2015 Oct;89(20):10383-98. doi: 10.1128/JVI.01653-15. Epub 2015 Aug 5.

28.

Predicting first traversal times for virions and nanoparticles in mucus with slowed diffusion.

Erickson AM, Henry BI, Murray JM, Klasse PJ, Angstmann CN.

Biophys J. 2015 Jul 7;109(1):164-72. doi: 10.1016/j.bpj.2015.05.034.

29.

HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers.

Sanders RW, van Gils MJ, Derking R, Sok D, Ketas TJ, Burger JA, Ozorowski G, Cupo A, Simonich C, Goo L, Arendt H, Kim HJ, Lee JH, Pugach P, Williams M, Debnath G, Moldt B, van Breemen MJ, Isik G, Medina-Ramírez M, Back JW, Koff WC, Julien JP, Rakasz EG, Seaman MS, Guttman M, Lee KK, Klasse PJ, LaBranche C, Schief WR, Wilson IA, Overbaugh J, Burton DR, Ward AB, Montefiori DC, Dean H, Moore JP.

Science. 2015 Jul 10;349(6244):aac4223. doi: 10.1126/science.aac4223. Epub 2015 Jun 18.

30.

Short Communication: Virion Aggregation by Neutralizing and Nonneutralizing Antibodies to the HIV-1 Envelope Glycoprotein.

Alexander MR, Sanders RW, Moore JP, Klasse PJ.

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1160-5. doi: 10.1089/AID.2015.0050. Epub 2015 Jul 20.

31.

What Do Chaotrope-Based Avidity Assays for Antibodies to HIV-1 Envelope Glycoproteins Measure?

Alexander MR, Ringe R, Sanders RW, Voss JE, Moore JP, Klasse PJ.

J Virol. 2015 Jun;89(11):5981-95. doi: 10.1128/JVI.00320-15. Epub 2015 Mar 25.

32.

Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer.

Derking R, Ozorowski G, Sliepen K, Yasmeen A, Cupo A, Torres JL, Julien JP, Lee JH, van Montfort T, de Taeye SW, Connors M, Burton DR, Wilson IA, Klasse PJ, Ward AB, Moore JP, Sanders RW.

PLoS Pathog. 2015 Mar 25;11(3):e1004767. doi: 10.1371/journal.ppat.1004767. eCollection 2015 Mar.

33.

The molecular basis of viral infection. Preface.

Klasse PJ.

Prog Mol Biol Transl Sci. 2015;129:xv-xix. doi: 10.1016/S1877-1173(14)00043-X. No abstract available.

PMID:
25595812
34.

Molecular determinants of the ratio of inert to infectious virus particles.

Klasse PJ.

Prog Mol Biol Transl Sci. 2015;129:285-326. doi: 10.1016/bs.pmbts.2014.10.012. Epub 2014 Dec 1. Review.

35.

A native-like SOSIP.664 trimer based on an HIV-1 subtype B env gene.

Pugach P, Ozorowski G, Cupo A, Ringe R, Yasmeen A, de Val N, Derking R, Kim HJ, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, Julien JP, Burton DR, Wilson IA, Sanders RW, Klasse PJ, Ward AB, Moore JP.

J Virol. 2015 Mar;89(6):3380-95. doi: 10.1128/JVI.03473-14. Epub 2015 Jan 14.

36.

Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.

Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, Imamichi H, Georgiev IS, Chuang GY, Druz A, Doria-Rose NA, Laub L, Sliepen K, van Gils MJ, de la Peña AT, Derking R, Klasse PJ, Migueles SA, Bailer RT, Alam M, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward AB, Mascola JR, Kwong PD, Connors M.

Nature. 2014 Nov 6;515(7525):138-42. doi: 10.1038/nature13601. Epub 2014 Sep 3.

37.

Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral antibody activity following acute infection.

Dugast AS, Stamatatos L, Tonelli A, Suscovich TJ, Licht AF, Mikell I, Ackerman ME, Streeck H, Klasse PJ, Moore JP, Alter G.

Eur J Immunol. 2014 Oct;44(10):2925-37. doi: 10.1002/eji.201344305. Epub 2014 Aug 11.

38.

Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.

Yasmeen A, Ringe R, Derking R, Cupo A, Julien JP, Burton DR, Ward AB, Wilson IA, Sanders RW, Moore JP, Klasse PJ.

Retrovirology. 2014 May 29;11:41. doi: 10.1186/1742-4690-11-41.

39.

Stable 293 T and CHO cell lines expressing cleaved, stable HIV-1 envelope glycoprotein trimers for structural and vaccine studies.

Chung NP, Matthews K, Kim HJ, Ketas TJ, Golabek M, de Los Reyes K, Korzun J, Yasmeen A, Sanders RW, Klasse PJ, Wilson IA, Ward AB, Marozsan AJ, Moore JP, Cupo A.

Retrovirology. 2014 Apr 25;11:33. doi: 10.1186/1742-4690-11-33.

40.

Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development?

Medina-Ramírez M, Sanders RW, Klasse PJ.

Expert Rev Vaccines. 2014 Apr;13(4):449-52.

41.

Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application.

Malcolm RK, Lowry D, Boyd P, Geer L, Veazey RS, Goldman L, Klasse PJ, Shattock RJ, Moore JP.

J Antimicrob Chemother. 2014 May;69(5):1325-9. doi: 10.1093/jac/dkt506. Epub 2013 Dec 30.

42.
43.

Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer.

Lyumkis D, Julien JP, de Val N, Cupo A, Potter CS, Klasse PJ, Burton DR, Sanders RW, Moore JP, Carragher B, Wilson IA, Ward AB.

Science. 2013 Dec 20;342(6165):1484-90. doi: 10.1126/science.1245627. Epub 2013 Oct 31.

44.

Crystal structure of a soluble cleaved HIV-1 envelope trimer.

Julien JP, Cupo A, Sok D, Stanfield RL, Lyumkis D, Deller MC, Klasse PJ, Burton DR, Sanders RW, Moore JP, Ward AB, Wilson IA.

Science. 2013 Dec 20;342(6165):1477-83. doi: 10.1126/science.1245625. Epub 2013 Oct 31.

45.

Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation.

Ringe RP, Sanders RW, Yasmeen A, Kim HJ, Lee JH, Cupo A, Korzun J, Derking R, van Montfort T, Julien JP, Wilson IA, Klasse PJ, Ward AB, Moore JP.

Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18256-61. doi: 10.1073/pnas.1314351110. Epub 2013 Oct 21.

46.

A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.

Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, Kim HJ, Blattner C, de la Peña AT, Korzun J, Golabek M, de Los Reyes K, Ketas TJ, van Gils MJ, King CR, Wilson IA, Ward AB, Klasse PJ, Moore JP.

PLoS Pathog. 2013 Sep;9(9):e1003618. doi: 10.1371/journal.ppat.1003618. Epub 2013 Sep 19.

47.

Structural biology. A new bundle of prospects for blocking HIV-1 entry.

Klasse PJ.

Science. 2013 Sep 20;341(6152):1347-8. doi: 10.1126/science.1245384. Epub 2013 Sep 12. No abstract available.

PMID:
24030494
48.

Influences on trimerization and aggregation of soluble, cleaved HIV-1 SOSIP envelope glycoprotein.

Klasse PJ, Depetris RS, Pejchal R, Julien JP, Khayat R, Lee JH, Marozsan AJ, Cupo A, Cocco N, Korzun J, Yasmeen A, Ward AB, Wilson IA, Sanders RW, Moore JP.

J Virol. 2013 Sep;87(17):9873-85. doi: 10.1128/JVI.01226-13. Epub 2013 Jul 3.

49.

Structural characterization of cleaved, soluble HIV-1 envelope glycoprotein trimers.

Khayat R, Lee JH, Julien JP, Cupo A, Klasse PJ, Sanders RW, Moore JP, Wilson IA, Ward AB.

J Virol. 2013 Sep;87(17):9865-72. doi: 10.1128/JVI.01222-13. Epub 2013 Jul 3.

50.

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120.

Kong L, Lee JH, Doores KJ, Murin CD, Julien JP, McBride R, Liu Y, Marozsan A, Cupo A, Klasse PJ, Hoffenberg S, Caulfield M, King CR, Hua Y, Le KM, Khayat R, Deller MC, Clayton T, Tien H, Feizi T, Sanders RW, Paulson JC, Moore JP, Stanfield RL, Burton DR, Ward AB, Wilson IA.

Nat Struct Mol Biol. 2013 Jul;20(7):796-803. doi: 10.1038/nsmb.2594. Epub 2013 May 26.

Supplemental Content

Loading ...
Support Center